Enasinib Tablets β Enasidenib 50 mg (30 Tabs) Everest
Enasinib 50 mg (Enasidenib) is a first-in-class targeted therapy and a generic equivalent to Idhifa. It acts as an inhibitor of the mutant IDH2 enzyme. Instead of directly killing cancer cells, it works by helping abnormal leukemia cells differentiate and mature into normal blood cells.
Manufacturer: Everest Pharmaceuticals (Bangladesh). This medication is specifically designed for patients with a confirmed mutation in the isocitrate dehydrogenase-2 (IDH2) gene.
Key Features:
- β Differentiation Agent: Promotes the maturation of myeloid blasts into normal neutrophils, restoring bone marrow function.
- β Precision Medicine: Highly effective for the specific subset of AML patients carrying the IDH2 mutation.
- β Convenience: Oral tablet formulation allows for daily home administration.
Prescribed by hematologists/oncologists for adult patients with:
- πΉ Acute Myeloid Leukemia (AML): Relapsed or refractory AML with a specific susceptible IDH2 mutation as detected by an FDA-approved test.
Sales Unit: Bottle containing 30 film-coated tablets (50 mg strength).
β οΈ APPLICATION INSTRUCTIONS:
- Standard Dosage: Typically 100 mg (two 50 mg tablets) taken orally once daily.
- Administration: Swallow tablets whole with a cup of water at the same time each day. Can be taken with or without food. Do not chew or split.
- Duration: Treatment is usually continued for a minimum of 6 months to allow time for clinical response, assuming no unacceptable toxicity occurs.
- β Missed Dose: Take as soon as possible on the same day. Resume normal schedule the next day. Do not double up.
- β Pregnancy & Breastfeeding: Strictly contraindicated. Can cause fetal harm. Effective contraception is mandatory.
- Pediatric patients (safety not established).
- Hypersensitivity to Enasidenib.
- Severe hepatic or renal impairment requires caution.
Strict medical supervision is required due to specific risks. Potential side effects include:
- β οΈ Differentiation Syndrome: A potentially life-threatening condition (symptoms: fever, dyspnea, fluid retention). Requires immediate medical intervention with corticosteroids.
- π©Έ Hematologic: Leukocytosis (high white blood cell count).
- πΆ Liver: Elevated bilirubin levels (jaundice).
- π€’ Gastrointestinal: Nausea, diarrhea, vomiting, decreased appetite.
What Customers Say
No reviews yet
Your review can be the first!